

# Carlos Marras

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6124259/publications.pdf>

Version: 2024-02-01

17  
papers

542  
citations

840119

11  
h-index

940134

16  
g-index

18  
all docs

18  
docs citations

18  
times ranked

915  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. <i>Immunotherapy</i> , 2021, 13, 433-458.	1.0	4
2	Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1616-1625.	2.9	14
3	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study. <i>Reumatología Clínica</i> , 2019, 15, 102-108.	0.2	27
4	Indicador compuesto para evaluar la calidad asistencial en el manejo de los pacientes con artritis reumatoide en las consultas externas de Reumatología. <i>Reumatología Clínica</i> , 2019, 15, 156-164.	0.2	5
5	Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature. <i>Reumatología Clínica</i> , 2019, 15, 34-42.	0.2	6
6	The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern. <i>Rheumatology International</i> , 2018, 38, 1735-1740.	1.5	3
7	Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 38-45.	1.6	117
8	Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study. <i>Rheumatology International</i> , 2017, 37, 1195-1202.	1.5	27
9	Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 423-430.	0.4	22
10	Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). <i>Medicine (United States)</i> , 2016, 95, e2891.	0.4	55
11	The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 126-132.	0.7	12
12	Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. <i>Rheumatology International</i> , 2015, 35, 1525-1534.	1.5	14
13	Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences. <i>Medicine (United States)</i> , 2015, 94, e267.	0.4	48
14	Efficacy of Tocilizumab in Conventional Treatment-Resistant Refractory Adult-Onset Still's Disease: Multicenter Retrospective Open-Label Study of Thirty-Four Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 1659-1665.	2.9	115
15	Diagnostic evaluation and classification criteria in Sjögren's Syndrome. <i>Joint Bone Spine</i> , 2009, 76, 44-49.	0.8	32
16	Évaluation diagnostique et critères de classification du syndrome de Sjögren. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2009, 76, 48-54.	0.0	0
17	Infliximab-Induced Vitiligo. <i>Dermatology</i> , 2005, 210, 79-80.	0.9	41